Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor, which has activity against VEGF-1–3, PDGFRα- β and KIT, resulting in tumor growth blockage and angiogenesis inhibition. The gene discussed is KIT; the disease is neoplasm.